Navigation Links
BIKAM and Dalton Medicinal Chemistry Sign Collaborative Research Agreement
Date:3/3/2008

BOSTON/Massachusetts, TORONTO/Canada, March 3 /PRNewswire/ - BIKAM, pioneers in the discovery and development of potential therapeutic agents for the treatment of degenerative eye diseases and ocular disorders and Dalton Medicinal Chemistry, have jointly announced an exclusive worldwide collaboration and agreement to discover and develop new therapeutics for unmet needs in ophthalmology.

Dalton Medicinal Chemistry will utilize their proprietary insights to advance several novel classes of compounds against selected BIKAM targets. BIKAM will advance these agents with their cutting edge battery of biological assays and delivery methodologies.

David Garvey, VP, Chemistry at BIKAM commented: "We are pleased to have the opportunity to work with the creative team at Dalton Medicinal Chemistry in the discovery and development of new entities for treating eye diseases. Their expertise, together with our propriety and leading position will quickly deliver important new medicines."

Judd Berman, Co-founder of Dalton Medicinal Chemistry, said: "We are delighted to have this opportunity to work with BIKAM in the discovery and development of much needed agents to treat these debilitating diseases".

About BIKAM

BIKAM, Inc., is a biopharmaceutical company focused on the development of novel therapeutics for the treatment of degenerative eye diseases and disorders. BIKAM is building a portfolio of product candidates based on patented technologies that were identified at the University of Florida, Gainesville. BIKAM investors include HealthCare Ventures, CHL Medical Partners and Fidelity Biosciences.

About Dalton Pharma Services & Dalton Medicinal Chemistry

Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada contract pharmaceutical manufacturer that supplies chemistry and analytical services to the biotechnology and pharmaceutical industries in the areas of chemistry and fine chemical manufacture. Dalton Medicinal Chemistry collaborates with select partners to deliver innovative, high quality medicinal chemistry capabilities to advance partners drug discovery pipelines. Dalton provides cGMP manufacturing and sterile filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its state of the art cGMP facilities, Dalton produces active pharmaceutical ingredients at the gram or kilogram scale. Dalton conducts sterile fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton's analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients.


'/>"/>
SOURCE Dalton Pharma Services
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
2. BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology
3. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
4. Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration
5. Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
6. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
7. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
8. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
9. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
10. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
11. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
Breaking Biology Technology:
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
Breaking Biology News(10 mins):